When will fusion power startup Commonwealth Fusion Systems go public?

Commonwealth Fusion Systems (CFS) is the best funded fusion power startup , having raised $4 billion from investors over the last seven years, including the $1 billion the company has raised now .

Now, developments at CFS , plus rumblings from industry sources TechCrunch has spoken with in recent months, suggest that the startup might go public in the next two or three years.

One of those developments was the appointment of Lorence Kim as CFS’s new Chief Financial Officer this week. Kim’s previous stint as a CFO was at Moderna, a biotech which specializes in mRNA therapies, which he joined in 2014 and subsequently helped take public in December 2018. He stuck around another year-and-a-half before returning to biotech investing.

Kim said he sees “something very familiar” in CFS. “Fusion today is where mRNA was a decade ago: scientifically real, commercially yet-to-be-proven, and closer than the consensus thinks,” he wrote in a LinkedIn post .

The choice might seem unusual, but Kim isn’t the first fusion executive to come with a background in the biotech world: Eric Lander, who helped lead the Human Genome Project, co-founded Pacific Fusion and now serves as its CEO.

“Lorence offers the unique experience of bringing to the world a completely novel, mission-driven product that sits at the intersection of breakthrough deep science, geopolitical urgency, and deployment at scale and speed,” Christine Dunn, head of external communications at CFS, told TechCrunch. She added that Kim said his arrival doesn’t necessarily mean that IPO preparations are underway.

Moderna took four-and-a-half years to IPO after Kim joined. But given the progress at CFS (and Kim’s recent arrival, protestations notwithstanding), the startup is likely to go public sooner than that.

A few points support our theory of a shorter timeline.

First, Moderna develops therapies for human diseases that don’t hit the market until they’re approved by the FDA, which requires data from lengthy and costly clinical trials. That timeline is driven by the fact that human lives are at stake.

With fusion, however, the potential of deadly errors is lower. Fusion reactors fizzle out instead of melting down, so they’re safer than fission reactors. Recognizing that, federal regulators have given the fusion industry guidelines that are distinct from the fission industry. In that sense, CFS has greater control over its destiny.